# A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Source: https://onco.cc/trials/nct06567782/  
OnCo record `nct06567782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer is a phase 2 interventional study registered as NCT06567782 by GlaxoSmithKline, with 120 participants planned, started 2025-02-18 and due to reach its primary completion in 2026-11-23. Interventions recorded: Dostarlimab and CAPEOX.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06567782
- Phase: 2
- Setting: A Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Participants With Previously Untreated T4N0 or Stage III MMRp/ MSS Colon Cancer
- Sponsor: GlaxoSmithKline
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06567782: https://clinicaltrials.gov/study/NCT06567782

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06567782.json